Your browser doesn't support javascript.
loading
The epidemiology of HIV population viral load in twelve sub-Saharan African countries.
Hladik, Wolfgang; Stupp, Paul; McCracken, Stephen D; Justman, Jessica; Ndongmo, Clement; Shang, Judith; Dokubo, Emily K; Gummerson, Elizabeth; Koui, Isabelle; Bodika, Stephane; Lobognon, Roger; Brou, Hermann; Ryan, Caroline; Brown, Kristin; Nuwagaba-Biribonwoha, Harriet; Kingwara, Leonard; Young, Peter; Bronson, Megan; Chege, Duncan; Malewo, Optatus; Mengistu, Yohannes; Koen, Frederix; Jahn, Andreas; Auld, Andrew; Jonnalagadda, Sasi; Radin, Elizabeth; Hamunime, Ndapewa; Williams, Daniel B; Kayirangwa, Eugenie; Mugisha, Veronicah; Mdodo, Rennatus; Delgado, Stephen; Kirungi, Wilford; Nelson, Lisa; West, Christine; Biraro, Samuel; Dzekedzeke, Kumbutso; Barradas, Danielle; Mugurungi, Owen; Balachandra, Shirish; Kilmarx, Peter H; Musuka, Godfrey; Patel, Hetal; Parekh, Bharat; Sleeman, Katrina; Domaoal, Robert A; Rutherford, George; Motsoane, Tsietso; Bissek, Anne-Cécile Zoung-Kanyi; Farahani, Mansoor.
Affiliation
  • Hladik W; Division of Global HIV and TB, US Centers for Disease Control and Prevention (CDC), Atlanta, GA, United States of America.
  • Stupp P; Division of Global HIV and TB, US Centers for Disease Control and Prevention (CDC), Atlanta, GA, United States of America.
  • McCracken SD; Division of Global HIV and TB, US Centers for Disease Control and Prevention (CDC), Atlanta, GA, United States of America.
  • Justman J; ICAP at Columbia University, New York, New York, United States of America.
  • Ndongmo C; Division of Global HIV and TB, US Centers for Disease Control and Prevention (CDC), Atlanta, GA, United States of America.
  • Shang J; Division of Global HIV and TB, US Centers for Disease Control and Prevention (CDC), Atlanta, GA, United States of America.
  • Dokubo EK; Division of Global HIV and TB, US Centers for Disease Control and Prevention (CDC), Atlanta, GA, United States of America.
  • Gummerson E; ICAP at Columbia University, New York, New York, United States of America.
  • Koui I; Ministry of Health, Abidjan, Cote d'Ivoire.
  • Bodika S; Division of Global HIV and TB, US Centers for Disease Control and Prevention (CDC), Atlanta, GA, United States of America.
  • Lobognon R; Division of Global HIV and TB, US Centers for Disease Control and Prevention (CDC), Atlanta, GA, United States of America.
  • Brou H; ICAP at Columbia University, New York, New York, United States of America.
  • Ryan C; Division of Global HIV and TB, US Centers for Disease Control and Prevention (CDC), Atlanta, GA, United States of America.
  • Brown K; Division of Global HIV and TB, US Centers for Disease Control and Prevention (CDC), Atlanta, GA, United States of America.
  • Nuwagaba-Biribonwoha H; ICAP at Columbia University, New York, New York, United States of America.
  • Kingwara L; National AIDS and STI's Control Programme, Ministry of Health, Nairobi, Kenya.
  • Young P; Division of Global HIV and TB, US Centers for Disease Control and Prevention (CDC), Atlanta, GA, United States of America.
  • Bronson M; Division of Global HIV and TB, US Centers for Disease Control and Prevention (CDC), Atlanta, GA, United States of America.
  • Chege D; ICAP at Columbia University, New York, New York, United States of America.
  • Malewo O; Division of Global HIV and TB, US Centers for Disease Control and Prevention (CDC), Atlanta, GA, United States of America.
  • Mengistu Y; Division of Global HIV and TB, US Centers for Disease Control and Prevention (CDC), Atlanta, GA, United States of America.
  • Koen F; ICAP at Columbia University, New York, New York, United States of America.
  • Jahn A; Ministry of Health, Lilongwe, Malawi.
  • Auld A; Division of Global HIV and TB, US Centers for Disease Control and Prevention (CDC), Atlanta, GA, United States of America.
  • Jonnalagadda S; Division of Global HIV and TB, US Centers for Disease Control and Prevention (CDC), Atlanta, GA, United States of America.
  • Radin E; ICAP at Columbia University, New York, New York, United States of America.
  • Hamunime N; Ministry of Health, Windhoek, Namibia.
  • Williams DB; Division of Global HIV and TB, US Centers for Disease Control and Prevention (CDC), Atlanta, GA, United States of America.
  • Kayirangwa E; Division of Global HIV and TB, US Centers for Disease Control and Prevention (CDC), Atlanta, GA, United States of America.
  • Mugisha V; ICAP at Columbia University, New York, New York, United States of America.
  • Mdodo R; Division of Global HIV and TB, US Centers for Disease Control and Prevention (CDC), Atlanta, GA, United States of America.
  • Delgado S; ICAP at Columbia University, New York, New York, United States of America.
  • Kirungi W; Ministry of Health, Kampala, Uganda.
  • Nelson L; Division of Global HIV and TB, US Centers for Disease Control and Prevention (CDC), Atlanta, GA, United States of America.
  • West C; Division of Global HIV and TB, US Centers for Disease Control and Prevention (CDC), Atlanta, GA, United States of America.
  • Biraro S; ICAP at Columbia University, New York, New York, United States of America.
  • Dzekedzeke K; ICAP at Columbia University, New York, New York, United States of America.
  • Barradas D; Division of Global HIV and TB, US Centers for Disease Control and Prevention (CDC), Atlanta, GA, United States of America.
  • Mugurungi O; Ministry of Health and Child Care, Harare, Zimbabwe.
  • Balachandra S; Division of Global HIV and TB, US Centers for Disease Control and Prevention (CDC), Atlanta, GA, United States of America.
  • Kilmarx PH; Division of Global HIV and TB, US Centers for Disease Control and Prevention (CDC), Atlanta, GA, United States of America.
  • Musuka G; ICAP at Columbia University, New York, New York, United States of America.
  • Patel H; Division of Global HIV and TB, US Centers for Disease Control and Prevention (CDC), Atlanta, GA, United States of America.
  • Parekh B; Division of Global HIV and TB, US Centers for Disease Control and Prevention (CDC), Atlanta, GA, United States of America.
  • Sleeman K; Division of Global HIV and TB, US Centers for Disease Control and Prevention (CDC), Atlanta, GA, United States of America.
  • Domaoal RA; Division of Global HIV and TB, US Centers for Disease Control and Prevention (CDC), Atlanta, GA, United States of America.
  • Rutherford G; University of California San Francisco, San Francisco, California, United States of America.
  • Motsoane T; Ministry of Health, Maseru, Lesotho.
  • Bissek AZ; Division of Operational Research for Health, Ministry of Health, Yaoundé, Cameroon.
  • Farahani M; Faculty of Medicine and Biomedical Sciences, University of Yaoundé, Yaoundé, Cameroon.
PLoS One ; 18(6): e0275560, 2023.
Article in En | MEDLINE | ID: mdl-37363921
BACKGROUND: We examined the epidemiology and transmission potential of HIV population viral load (VL) in 12 sub-Saharan African countries. METHODS: We analyzed data from Population-based HIV Impact Assessments (PHIAs), large national household-based surveys conducted between 2015 and 2019 in Cameroon, Cote d'Ivoire, Eswatini, Kenya, Lesotho, Malawi, Namibia, Rwanda, Tanzania, Uganda, Zambia, and Zimbabwe. Blood-based biomarkers included HIV serology, recency of HIV infection, and VL. We estimated the number of people living with HIV (PLHIV) with suppressed viral load (<1,000 HIV-1 RNA copies/mL) and with unsuppressed viral load (viremic), the prevalence of unsuppressed HIV (population viremia), sex-specific HIV transmission ratios (number female incident HIV-1 infections/number unsuppressed male PLHIV per 100 persons-years [PY] and vice versa) and examined correlations between a variety of VL metrics and incident HIV. Country sample sizes ranged from 10,016 (Eswatini) to 30,637 (Rwanda); estimates were weighted and restricted to participants 15 years and older. RESULTS: The proportion of female PLHIV with viral suppression was higher than that among males in all countries, however, the number of unsuppressed females outnumbered that of unsuppressed males in all countries due to higher overall female HIV prevalence, with ratios ranging from 1.08 to 2.10 (median: 1.43). The spatial distribution of HIV seroprevalence, viremia prevalence, and number of unsuppressed adults often differed substantially within the same countries. The 1% and 5% of PLHIV with the highest VL on average accounted for 34% and 66%, respectively, of countries' total VL. HIV transmission ratios varied widely across countries and were higher for male-to-female (range: 2.3-28.3/100 PY) than for female-to-male transmission (range: 1.5-10.6/100 PY). In all countries mean log10 VL among unsuppressed males was higher than that among females. Correlations between VL measures and incident HIV varied, were weaker for VL metrics among females compared to males and were strongest for the number of unsuppressed PLHIV per 100 HIV-negative adults (R2 = 0.92). CONCLUSIONS: Despite higher proportions of viral suppression, female unsuppressed PLHIV outnumbered males in all countries examined. Unsuppressed male PLHIV have consistently higher VL and a higher risk of transmitting HIV than females. Just 5% of PLHIV account for almost two-thirds of countries' total VL. Population-level VL metrics help monitor the epidemic and highlight key programmatic gaps in these African countries.
Subject(s)

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: HIV Infections / Anti-HIV Agents Type of study: Risk_factors_studies / Screening_studies Limits: Adult / Female / Humans / Male Country/Region as subject: Africa Language: En Journal: PLoS One Journal subject: CIENCIA / MEDICINA Year: 2023 Document type: Article Affiliation country: Country of publication:

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: HIV Infections / Anti-HIV Agents Type of study: Risk_factors_studies / Screening_studies Limits: Adult / Female / Humans / Male Country/Region as subject: Africa Language: En Journal: PLoS One Journal subject: CIENCIA / MEDICINA Year: 2023 Document type: Article Affiliation country: Country of publication: